Baidu
map

Diabetes Care:砷和糖尿病有啥关系?

2016-11-10 MedSci MedSci原创

青年中,砷和糖尿病的关联是鲜为人知的。我们研究了砷与1型和2型糖尿病的关联。因为一碳代谢影响砷代谢,我们也评估了叶酸和维生素B12,与砷代谢对糖尿病患病率的潜在的相互作用。 研究纳入688例患者,年龄<22岁,1型和2型糖尿病分别有429例和85例,还有174例对照参与者。测量血浆砷(无机砷[iAs]、单甲基化砷[MMA]、二甲基化砷[DMA])和一碳代谢标志物(叶酸和维生素B12)。

青年中,砷和糖尿病的关联是鲜为人知的。我们研究了砷与1型和2型糖尿病的关联。因为一碳代谢影响砷代谢,我们也评估了叶酸和维生素B12,与砷代谢对糖尿病患病率的潜在的相互作用。

研究纳入688例患者,年龄<22岁,1型和2型糖尿病分别有429例和85例,还有174例对照参与者。测量血浆砷(无机砷[iAs]、单甲基化砷[MMA]、二甲基化砷[DMA])和一碳代谢标志物(叶酸和维生素B12)。

中位数∑As、iAs%、MMA%和DMA%分别为83.1 ng/L、63.4%、10.3%和25.2%。∑As与任何一型糖尿病都不相关。对于1型糖尿病,iAs%、MMA%和DMA%不同四分位范围比较,充分校正后的OR值分别为0.68 (0.50-0.91)、1.33 (1.02-1.74)和1.28 (1.01-1.63);对于2型糖尿病,分别为0.82 (0.48-1.39)、1.09 (0.65-1.82)和1.17 (0.77-1.77)。在相互作用分析中,血浆叶酸水平高于和低于中位数的参与者中,MMA%对1型糖尿病的OR值分别为1.80 (1.25-2.58)和0.98 (0.70-1.38)(交互作用P = 0.02)。

结果表明,低iAs% vs 高MMA%和DMA%,1型糖尿病可能性更高,与不同叶酸水平有潜在的相互作用。这些数据支持进一步研究砷代谢对1型糖尿病的作用,包括与一个碳代谢生物标志物的相互作用。

原始出处:

Grau-Pérez M,et al.The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study.Diabetes Care. 2016 Nov 3. pii: dc160810. [Epub ahead of print]

本文系梅斯医学(MedSci)原 创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901499, encodeId=525b190149991, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 27 11:34:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759813, encodeId=26201e5981301, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 31 10:34:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637538, encodeId=63cc163e5387f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Feb 17 16:34:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155593, encodeId=25e21555932e, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Nov 14 07:13:11 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595968, encodeId=07981595968f3, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Sat Nov 12 11:34:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901499, encodeId=525b190149991, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 27 11:34:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759813, encodeId=26201e5981301, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 31 10:34:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637538, encodeId=63cc163e5387f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Feb 17 16:34:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155593, encodeId=25e21555932e, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Nov 14 07:13:11 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595968, encodeId=07981595968f3, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Sat Nov 12 11:34:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901499, encodeId=525b190149991, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 27 11:34:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759813, encodeId=26201e5981301, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 31 10:34:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637538, encodeId=63cc163e5387f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Feb 17 16:34:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155593, encodeId=25e21555932e, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Nov 14 07:13:11 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595968, encodeId=07981595968f3, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Sat Nov 12 11:34:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901499, encodeId=525b190149991, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 27 11:34:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759813, encodeId=26201e5981301, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 31 10:34:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637538, encodeId=63cc163e5387f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Feb 17 16:34:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155593, encodeId=25e21555932e, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Nov 14 07:13:11 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595968, encodeId=07981595968f3, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Sat Nov 12 11:34:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
    2016-11-14 忠诚向上

    好好看下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1901499, encodeId=525b190149991, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 27 11:34:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759813, encodeId=26201e5981301, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Mar 31 10:34:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637538, encodeId=63cc163e5387f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Feb 17 16:34:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155593, encodeId=25e21555932e, content=好好看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Nov 14 07:13:11 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595968, encodeId=07981595968f3, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Sat Nov 12 11:34:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
    2016-11-12 lishizhe

相关资讯

EHP:砷污染与不良妊娠结局和婴儿死亡率相关

砷暴露是目前全球主要的健康问题之一,全球已经有超过3亿人受到其影响,但目前砷对人类生殖的影响尚不明确。Quansah R等人检索了PubMed、Ovid MEDLINE、EMBASE等数据库收集相关文献,探究该问题。该研究包括23篇文献用于系统回顾,16篇文献提供了足够数据进行定量分析。研究结果显示,地下水中砷浓度≥50μg/L会增加自然流产的风险(6篇研究 OR=1.98;95%CI:1.27

砷超标 冬虫夏草还能不能吃?

冬虫夏草因为其提高免疫力等功效,成为很多病后需要调养人群的首选。不过,近日,国家食品药品监督管理总局日前发布虫草消费提示,虫草中砷含量超标近10倍。在国家食药监总局组织的对冬虫夏草、冬虫夏草粉及纯粉片产品的监测检验中,发现其中的砷含量为4.4~9.9 mg/kg。 食药监总局的消费提示强调:“有关专家分析研判,保健食品国家安全标准中砷限量值为1.0 mg/kg,长期食用冬虫夏草、冬虫夏草粉及纯粉

砷中毒可引发癌症

  世界卫生组织1月2日在日内瓦发布一份文件指出,砷中毒可引发癌症等一些严重疾病,提醒公众重视砷中毒对健康的影响。   世卫组织称,砷存在于空气、水和土壤中,以有机和无机两种形式存在,无机砷毒性较大。砷作为合金添加剂被广泛应用于玻璃加工、印染、纺织、造纸等生产中。   世卫组织强调,饮用和食用被砷污染的水和食物、吸烟都可能会摄入砷,若人体接触被砷污染的工业用水、农业灌溉用水等,也可能会受到危害

极草被勒令停产,或将永久告别保健品行列

新闻直击2016年2月26日,国家食品药品监督管理总局发布了停止冬虫夏草用于保健食品试点工作的通知,自此国食药监保化〔2012〕225号文件停止执行。通知简短但意义重大,这就意味着北京、江西、湖北、广东、青海等这些试点省市不再拥有销售冬虫夏草保健食品的权利,市面上也将不再看到作为保健品的冬虫夏草制品了。3 月 30 日,青海春天正式发布公告,向公众回应国家食药监总局要求其立即停止生产经营冬虫夏草纯

Epidemiology:孕期饮用水中砷浓度影响宝宝出生体重

目前关于孕期砷暴露和新生儿出生体重的关系并不明确。研究者进行了一项研究,评估产前砷暴露和出生体重之间的因果关系,考虑到孕龄和产妇在怀孕期间体重增加等因素对新生儿出生体重的潜在影响,研究者使用结构方程模型(SEMs)对数据进行分析。该前瞻性研究纳入了2008-2011年孟加拉国的孕妇。在纳入研究时对1140名孕周小于16周的孕妇检测去饮用水里砷浓度,产后1个月内对624名产妇检测脚趾甲里砷含量。使用

Baidu
map
Baidu
map
Baidu
map